Tesamorelin

What Is Tesamorelin?

Tesamorelin is a synthetic analogue of:

GHRH — Growth Hormone-Releasing Hormone.

GHRH is a natural hormone released by the hypothalamus.

Its job is to signal the pituitary gland:

“release growth hormone.”

Tesamorelin mimics that signal.

The pathway looks roughly like:

Tesamorelin → GHRH receptor → pituitary → growth hormone → IGF-1

That makes it very different from directly administering recombinant human growth hormone.

Tesamorelin stimulates the body’s own GH secretion rather than supplying GH itself.

Is Tesamorelin FDA Approved?

Yes.

Tesamorelin was first approved by FDA in November 2010.

Current FDA-approved products include:

Egrifta SV

and:

Egrifta WR.

FDA’s current product database lists both as prescription tesamorelin products. 

The current approved indication is very specific:

reduction of excess abdominal fat in adults with HIV and lipodystrophy.

Current FDA labeling explicitly says tesamorelin is not indicated for weight-loss management because it is considered weight neutral. 

That distinction matters enormously.

What Is HIV-Associated Lipodystrophy?

Some people living with HIV—particularly those exposed to certain older antiretroviral therapies—develop abnormal changes in how body fat is distributed.

This can include:

• Excess visceral abdominal fat
• Enlarged abdominal appearance
• Loss of fat in the face or limbs
• Metabolic abnormalities
• Changes in cholesterol and triglycerides

The abnormal accumulation of deep abdominal fat is sometimes called:

HIV-associated abdominal lipohypertrophy.

Tesamorelin was developed specifically to reduce this type of:

visceral adipose tissue — VAT.

What Is Visceral Fat?

Not all body fat behaves the same way.

Subcutaneous fat

sits underneath the skin.

Visceral fat

sits deeper inside the abdomen around internal organs.

Visceral fat is especially metabolically active and is associated with:

• Insulin resistance
• Abnormal lipids
• Cardiovascular disease
• Fatty liver
• Chronic inflammation
• Metabolic syndrome

Tesamorelin’s clinical development focused specifically on reducing visceral abdominal fat, not simply reducing scale weight.

Does Tesamorelin Actually Reduce Visceral Fat?

Yes.

This is one of the strongest parts of its evidence base.

A large randomized controlled trial enrolled 412 adults with HIV and excess abdominal fat.

After 26 weeks:

visceral adipose tissue decreased 15.2% with tesamorelin

while:

visceral fat increased 5.0% with placebo.

Triglycerides also improved substantially. 

Another randomized study involving 404 adults found visceral fat decreased about:

10.9% after six months

and roughly:

18% after twelve months

among those continuing tesamorelin. 

So tesamorelin’s ability to reduce visceral fat in its approved population is well established.

Does Tesamorelin Cause Weight Loss?

Not necessarily.

This is where people often get confused.

Tesamorelin can reduce deep abdominal fat while leaving overall body weight relatively unchanged.

FDA specifically states:

Egrifta WR is not indicated for weight-loss management because it has a weight-neutral effect. 

That’s very different from drugs such as:

semaglutide + tirzepatide + retatrutide

which can produce large reductions in total body weight.

Tesamorelin is better thought of as:

a visceral-fat redistribution medication

rather than:

a general obesity medication.

Does Tesamorelin Target Belly Fat?

In its approved population:

yes, specifically visceral abdominal fat.

That’s unusually specific.

A randomized clinical trial found tesamorelin reduced visceral adipose tissue by about 34 cm², while placebo showed an increase of about 8 cm² over six months. 

But this does not mean tesamorelin is proven to selectively remove ordinary cosmetic belly fat in anyone who wants a smaller waist.

The evidence comes primarily from people with:

HIV-associated abdominal fat accumulation.

What Happens to Subcutaneous Fat?

This is an interesting distinction.

In the 404-person randomized trial, tesamorelin reduced:

visceral fat + trunk fat + waist circumference

without significantly reducing limb or abdominal subcutaneous fat. 

That reinforces the idea that its effect is not simply:

“burn all body fat.”

It appears particularly effective against visceral fat.

What Happens When Tesamorelin Is Stopped?

The effect is not permanent.

In the long-term study, people who continued tesamorelin maintained an approximately:

18% reduction in visceral fat.

But people switched from tesamorelin to placebo regained much of the visceral fat. 

So tesamorelin does not appear to permanently “reset” fat distribution.

This is another recurring theme in metabolic medicine:

changing the signal works while the signal is being changed.

Once the treatment is removed, underlying biology can return.

How Does Tesamorelin Reduce Visceral Fat?

Tesamorelin increases:

endogenous growth hormone secretion.

Growth hormone influences:

• Lipolysis
• Fat metabolism
• Protein metabolism
• IGF-1 production
• Body composition

Visceral fat appears particularly responsive to GH signaling.

By restoring stronger pulsatile GH signaling, tesamorelin can increase mobilization of visceral fat.

But:

GH biology is complex.

“More GH = more fat loss” is not a safe or accurate rule.

What About IGF-1?

Tesamorelin increases:

IGF-1 — insulin-like growth factor 1.

That’s expected because growth hormone stimulates IGF-1 production.

FDA labeling specifically warns that tesamorelin can cause elevated IGF-1 and recommends monitoring because the effects of prolonged elevations are not fully known. 

IGF-1 participates in:

• Growth
• Protein synthesis
• Tissue repair
• Cell survival
• Metabolism

But chronically excessive IGF-1 signaling is not automatically beneficial.

What About Liver Fat?

This is one of the most interesting tesamorelin research areas beyond its approved indication.

A randomized trial involving adults with HIV and abdominal fat accumulation found tesamorelin reduced both:

visceral fat

and:

liver fat. 

A later randomized multicenter trial enrolled 61 people with HIV and fatty liver disease.

After 12 months, tesamorelin produced approximately:

a 37% relative reduction in liver fat

compared with placebo.

About:

35% of tesamorelin participants

had liver fat below the diagnostic threshold of 5%, compared with:

4% receiving placebo. 

That’s a meaningful human signal.

Does Tesamorelin Treat Fatty Liver Disease?

Not broadly.

The liver-fat studies were specifically conducted in people with:

HIV + fatty liver disease.

That population is biologically distinct from the much larger population with metabolic fatty liver associated with obesity and insulin resistance.

So:

fatty liver research → yes

but:

FDA-approved MASLD/MASH treatment → no.

This is an area where Wegovy now has a much more specific FDA-approved MASH indication.

What About Liver Fibrosis?

The HIV fatty-liver trial also examined markers related to liver disease progression.

Researchers found that tesamorelin reduced liver fat and appeared to prevent progression of fibrosis in that study population. 

That’s scientifically interesting.

But the study was small.

We should not turn that into:

“tesamorelin reverses liver fibrosis.”

It hasn’t been established as a general antifibrotic drug.

What About Triglycerides?

Tesamorelin can improve triglycerides in its approved population.

In one large randomized trial:

triglycerides decreased about 50 mg/dL with tesamorelin

while they increased about 9 mg/dL with placebo. 

Longer-term research also found the reduction persisted during continued treatment. 

So lipid improvement is a legitimate secondary metabolic effect.

What About Cholesterol?

Some trials found improvements in:

• Total cholesterol
• Total cholesterol/HDL ratio
• Triglycerides

But tesamorelin isn’t primarily a cholesterol medication.

Its strongest effect remains:

visceral fat reduction.

What About Insulin Resistance?

This is complicated.

GH signaling can increase fat breakdown.

But excessive GH can also reduce insulin sensitivity.

So tesamorelin has the potential to produce both:

beneficial body-composition changes

and:

worsening glucose metabolism in susceptible individuals.

FDA labeling warns that tesamorelin can cause:

glucose intolerance or diabetes.

Glucose status should therefore be evaluated before and during treatment. 

Does Tesamorelin Cause Diabetes?

Not in most people.

Large trials did not show catastrophic glucose deterioration across the entire treatment population.

For example, the 404-person study found no significant overall glucose abnormalities during treatment. 

And the liver-fat trial found no significant difference in fasting glucose or HbA1c between tesamorelin and placebo after 12 months. 

But individual risk matters.

The GH/IGF-1 pathway can impair insulin sensitivity, so people with diabetes or high diabetes risk require appropriate monitoring.

What About Muscle?

Growth hormone and IGF-1 influence:

• Protein metabolism
• Lean mass
• Muscle biology

Tesamorelin can shift body composition while reducing visceral fat.

But it is not approved as a:

muscle-building drug.

There is no good evidence showing it produces bodybuilding-style hypertrophy in healthy people.

Does Tesamorelin Build Lean Mass?

Some GHRH studies show changes in lean mass.

But the strongest tesamorelin evidence involves:

reducing visceral adipose tissue.

Increasing “lean mass” on a body-composition scan doesn’t necessarily mean:

dramatically larger muscles + greater strength + athletic enhancement.

Those outcomes must be measured separately.

What About Anti-Aging?

This is one of the most common off-label marketing angles.

Growth hormone secretion declines with age.

So the reasoning goes:

aging → less GH → tesamorelin increases GH → therefore tesamorelin reverses aging.

That final step does not follow.

GH and IGF-1 are involved in growth and repair.

But longevity biology is complicated.

In some animal models:

reduced GH/IGF-1 signaling is actually associated with longer lifespan.

So “more youthful GH” should not automatically be interpreted as:

longer life.

Tesamorelin has not been shown to extend human lifespan or reverse biological aging.

What About Cognition?

This is where tesamorelin becomes unexpectedly interesting.

A randomized, double-blind, placebo-controlled trial enrolled:

152 adults aged 55–87

including 66 with mild cognitive impairment.

Participants received tesamorelin or placebo for 20 weeks.

Researchers found an overall favorable cognitive effect, particularly in:

executive function.

IGF-1 increased about:

117%

while remaining within the physiological range. 

That’s legitimate human evidence.

Does Tesamorelin Improve Memory?

Possibly in certain older populations—but the evidence is preliminary.

In the 152-person study:

executive function improved significantly

while:

verbal memory showed a trend

and:

visual memory did not significantly improve.

So saying:

“tesamorelin improves cognition”

has some support.

Saying:

“tesamorelin dramatically boosts memory”

would overstate the findings.

What About Mild Cognitive Impairment?

The same study included adults with:

MCI — mild cognitive impairment.

The cognitive benefit appeared similar in people with MCI and cognitively healthy older adults. 

That’s interesting enough that GHRH signaling continues to be investigated for brain aging.

But tesamorelin is:

not FDA approved for MCI.

And this study does not establish prevention of Alzheimer’s disease.

Is There New Cognitive Research?

Yes.

A 2026 double-blind placebo-controlled pilot study evaluated low-dose tesamorelin in 22 adults whose cognition ranged from normal to mild cognitive impairment.

The study examined changes in:

cognition + brain connectivity

after ten weeks.

This is very recent and adds to continuing interest in GHRH signaling and brain aging, but 22 participants is still a small pilot—not definitive evidence. 

What About GABA?

A substudy of the older cognition trial evaluated brain:

GABA — gamma-aminobutyric acid.

Thirty participants underwent brain magnetic resonance spectroscopy.

The study examined whether changes in GABA could help explain cognitive effects produced by tesamorelin/GHRH signaling. 

So tesamorelin’s brain effects may involve more than simply:

“more IGF-1.”

Neurotransmitter and network-level changes are active areas of research.

Does Tesamorelin Prevent Alzheimer’s Disease?

No evidence establishes that.

Age-related changes in:

GH + GHRH + IGF-1

are relevant to brain aging.

And the cognition studies are genuinely interesting.

But we do not have evidence showing tesamorelin:

• Prevents Alzheimer’s
• Slows Alzheimer’s progression
• Reverses dementia
• Stops neurodegeneration

Those claims are much stronger than current data.

What About Brain Fog?

Because tesamorelin has human cognitive research, “brain fog” is a reasonable discovery term.

But brain fog is nonspecific and can result from:

• Sleep problems
• Hormonal disorders
• Medication effects
• Anxiety
• Depression
• Infection
• Nutritional deficiencies
• Neurological disease

Tesamorelin has not been established as a general brain-fog treatment.

What About Sleep?

Natural GH secretion is strongly associated with sleep, especially:

slow-wave sleep.

That creates interest in GHRH peptides for sleep.

But tesamorelin is not an approved sleep medication.

Any improvement in sleep has not been established strongly enough to call it a treatment for:

insomnia + poor sleep + sleep apnea.

Tesamorelin vs. Sermorelin

These are closely related—but distinctly different.

Sermorelin

is essentially:

GHRH(1–29).

It was historically FDA approved for certain pediatric growth-hormone and diagnostic uses but is no longer marketed as an approved product.

Tesamorelin

is a modified:

GHRH(1–44) analogue

designed to resist enzymatic degradation.

It remains FDA approved today.

And importantly, tesamorelin has large Phase 3 human trials demonstrating:

reduction of HIV-associated visceral abdominal fat.

So tesamorelin has a far stronger current pharmaceutical evidence base.

Tesamorelin vs. CJC-1295 No DAC

Both stimulate the:

GHRH receptor.

But their evidence bases are dramatically different.

Tesamorelin

Has:

• Large controlled human trials
• Defined pharmaceutical formulation
• FDA approval
• Established indication
• Known clinical safety profile

CJC-1295 No DAC / Modified GRF(1–29)

Has:

• Much thinner direct human evidence
• No FDA-approved product
• Heavy reliance on extrapolation from related GHRH compounds

So a claim proven for tesamorelin cannot simply be transferred to CJC No DAC.

Tesamorelin vs. Ipamorelin

Tesamorelin

acts through:

GHRH receptor.

Ipamorelin

acts through:

GHS-R1a / ghrelin receptor.

Both can stimulate growth hormone, but through different upstream signals.

That’s why modern peptide clinics sometimes combine them.

However, there is not strong clinical evidence proving:

tesamorelin + ipamorelin

provides superior fat loss, muscle growth, anti-aging, sleep, or recovery outcomes.

The mechanisms may complement each other.

Clinical synergy still requires clinical evidence.

Tesamorelin vs. HGH

Tesamorelin

stimulates the pituitary to release endogenous GH.

Recombinant HGH / Somatropin

provides growth hormone directly.

That means tesamorelin retains some of the body’s normal regulatory architecture.

But it still increases:

GH + IGF-1.

So it is not free of the biological risks associated with stimulating that pathway.

Tesamorelin vs. GLP-1 Medications

Completely different.

Tesamorelin

Primarily:

GH/GHRH signaling → visceral fat reduction.

Semaglutide

GLP-1 → appetite regulation + glucose control + weight loss.

Tirzepatide

GIP + GLP-1 → appetite/metabolic regulation.

Tesamorelin is not competing in the same category of general obesity treatment.

FDA actually specifies that it is:

weight neutral. 

Does Tesamorelin Cause Cancer?

This needs careful wording.

No evidence means we can simply say tesamorelin “causes cancer.”

But GH and IGF-1 are:

growth-promoting signals.

That raises legitimate concerns when an existing tumor is present.

FDA therefore contraindicates tesamorelin in people with:

active malignancy.

For people with a history of cancer, the risks and benefits require careful consideration because stimulating GH/IGF-1 could theoretically influence tumor biology. 

That’s precaution based on biology and risk—not proof tesamorelin causes cancer in healthy people.

What About Pituitary Problems?

Tesamorelin depends on a functioning:

hypothalamic-pituitary axis.

Current FDA labeling contraindicates it in people with disruption of that system from conditions such as:

• Hypophysectomy
• Hypopituitarism
• Pituitary tumor or surgery
• Head irradiation
• Certain head injuries

because the pituitary may not respond normally. 

What About Pregnancy?

Tesamorelin is contraindicated during pregnancy.

Why?

Its approved purpose is to reduce visceral fat.

During pregnancy, changes in body fat are a normal and necessary physiological adaptation.

FDA states that modifying visceral adipose tissue during pregnancy offers no benefit and could cause fetal harm. 

What About Side Effects?

Current FDA labeling includes adverse effects involving:

• Injection-site reactions
• Joint pain
• Muscle pain
• Peripheral swelling
• Hypersensitivity reactions
• Elevated IGF-1
• Glucose intolerance

The GH/IGF-1 pathway explains several of these effects.

Fluid retention in particular can produce:

swelling + joint discomfort + stiffness.

Can Tesamorelin Cause Carpal Tunnel?

GH-related medications can cause fluid retention and soft-tissue swelling.

That can contribute to:

carpal tunnel-like symptoms

in susceptible individuals.

This fits the broader GH-axis adverse-effect profile.

But it should not be described as something that happens to everyone.

Evidence Snapshot

Defined Synthetic Peptide: Yes
GHRH Receptor Mechanism: Strong
Human GH-Stimulation Evidence: Strong
IGF-1 Effects: Strong
Human Phase 3 Trials: Yes
HIV Visceral-Fat Reduction: Strong
FDA Approved: Yes
Current Brands: Egrifta SV / Egrifta WR
General Weight-Loss Indication: No
FDA Label Says Weight Neutral: Yes
Liver-Fat Research in HIV: Positive human trials
MASH/MASLD Approval: No
Cognition Research: Interesting human evidence
Mild Cognitive Impairment Research: Yes, preliminary
Anti-Aging Evidence: Insufficient
Human Lifespan Extension: No evidence
Muscle-Building Indication: No
Overall Evidence: One of the strongest clinically validated GHRH peptides, with clear efficacy for HIV-associated visceral abdominal fat and meaningful additional human research in liver and brain biology. 

What Do We Know?

We know tesamorelin:

stimulates the endogenous GH/IGF-1 axis.

We know it reduces:

visceral abdominal fat

in adults with HIV-associated lipodystrophy.

Large controlled trials demonstrated visceral-fat reductions around 15–20%, depending on study duration and population. 

We know the effect tends to diminish after treatment stops. 

We also have human evidence suggesting meaningful reductions in:

liver fat

among people with HIV and fatty liver disease. 

And there is legitimate human research suggesting possible effects on:

executive function and brain aging. 

That’s a much stronger evidence base than most peptides in this library.

What Don’t We Know?

We don’t have strong evidence proving tesamorelin:

• Causes major overall weight loss
• Treats ordinary obesity
• Permanently eliminates belly fat
• Keeps visceral fat off after discontinuation
• Treats all forms of fatty liver
• Treats MASH generally
• Reverses liver fibrosis
• Builds substantial muscle
• Dramatically improves strength
• Improves athletic performance
• Accelerates injury recovery
• Reverses aging
• Extends human lifespan
• Eliminates fatigue
• Reliably improves sleep
• Treats Alzheimer’s disease
• Prevents dementia
• Treats ADHD
• Eliminates brain fog
• Improves cognition in young healthy adults
• Produces proven synergy with ipamorelin or other GH secretagogues

Those claims go beyond the established evidence.

Research & Regulatory Status

Tesamorelin is a fully legitimate FDA-approved pharmaceutical.

FDA first approved tesamorelin in:

November 2010. 

Current licensed products include:

Egrifta SV

and:

Egrifta WR. 

Their approved indication is:

reduction of excess abdominal fat in adults with HIV and lipodystrophy.

FDA specifically warns that:

tesamorelin is not indicated for weight-loss management and has a weight-neutral effect. 

So someone using the phrase:

“FDA-approved fat-loss peptide”

is technically leaving out an extremely important part of the story.

A better description is:

FDA-approved visceral-fat-reduction therapy for a specific HIV-associated condition.

Research-Market Tesamorelin vs. Egrifta

This is another crucial distinction.

Egrifta SV / Egrifta WR

are regulated FDA-approved tesamorelin products with:

• Verified identity
• Defined formulation
• Manufacturing controls
• Clinical-trial validation
• FDA-reviewed labeling

A research vial labeled “tesamorelin”

is not automatically equivalent.

The fact that pharmaceutical tesamorelin works does not prove that an online vial contains:

the correct molecule + correct concentration + appropriate purity + appropriate sterility.

The molecule has excellent evidence.

The individual product still has to be trustworthy.

Your Pep Resource Takeaway

Tesamorelin is one of the compounds where the real science is actually more interesting than the peptide-clinic pitch.

It has:

a clear mechanism + large human trials + FDA approval + measurable changes in visceral fat.

In a 412-person randomized trial, visceral fat fell about:

15.2%

while placebo participants actually gained visceral fat. 

Longer treatment produced reductions around:

18%. 

And researchers later found tesamorelin could reduce liver fat by roughly:

37% relative to baseline

in adults with HIV-associated fatty liver disease. 

Even more unexpectedly, a randomized trial in older adults found favorable effects on:

executive cognitive function. 

So there is plenty of legitimate science here.

Where marketing gets sloppy is turning:

“reduces visceral fat in HIV-associated lipodystrophy”

into:

“melts stubborn belly fat for everyone.”

FDA itself explicitly says tesamorelin is:

not a weight-loss medication and is weight neutral. 

The cleanest 2026 description is:

Tesamorelin is a clinically validated GHRH analogue that meaningfully reduces visceral abdominal fat in adults with HIV-associated lipodystrophy, with additional promising research involving liver fat and cognition—but its approved and proven effects should not be generalized into a universal fat-loss, bodybuilding, or anti-aging therapy.

Research Areas / Search Keywords

Tesamorelin, tesamorelin peptide, Egrifta, Egrifta SV, Egrifta WR, Egrifta tesamorelin, growth hormone releasing hormone, growth hormone-releasing hormone, GHRH, GHRH analogue, GHRH peptide, growth hormone releasing factor, GRF, hypothalamus, pituitary gland, pituitary growth hormone, growth hormone, GH, HGH research, endogenous growth hormone, natural growth hormone release, GH pulse, pulsatile growth hormone, IGF-1, IGF1, insulin-like growth factor 1, GH IGF-1 axis, somatotropic axis, HIV, HIV lipodystrophy, HIV-associated lipodystrophy, HIV abdominal fat, HIV belly fat, HIV visceral fat, HIV lipohypertrophy, antiretroviral therapy, ART, antiretroviral-associated fat changes, visceral adipose tissue, visceral fat, VAT, deep belly fat, abdominal fat, abdominal obesity, central fat, central adiposity, belly fat, stubborn belly fat, stomach fat, visceral obesity, waist circumference, waist-to-hip ratio, trunk fat, subcutaneous fat, body fat distribution, fat redistribution, body composition, fat metabolism, lipolysis, lipolytic hormone, weight loss research, weight management, obesity research, tesamorelin weight loss, tesamorelin belly fat, tesamorelin visceral fat, tesamorelin before and after research, tesamorelin body composition, metabolic health, metabolic syndrome, insulin resistance, insulin sensitivity, glucose intolerance, diabetes risk, blood sugar, fasting glucose, A1C research, HbA1c, glucose metabolism, triglycerides, high triglycerides, cholesterol, lipids, dyslipidemia, cardiovascular risk research, heart disease research, fatty liver, liver fat, hepatic fat, NAFLD research, MASLD research, MASH research, NASH research, HIV fatty liver, liver fibrosis research, liver health, liver inflammation, hepatic steatosis, muscle mass research, lean mass, lean body mass, muscle growth research, bodybuilding research, workout recovery research, exercise recovery, athletic performance research, anti-aging, anti-aging peptide, longevity research, somatopause, age-related GH decline, healthy aging, biological aging, brain health, cognition, cognitive function, cognitive enhancement research, executive function, memory, verbal memory, mild cognitive impairment, MCI, brain aging, cognitive decline, Alzheimer’s research, dementia research, brain fog, mental clarity research, GABA research, brain connectivity, neuroendocrine research, neuroplasticity research, sleep research, slow-wave sleep, deep sleep research, energy, fatigue research, low energy, vitality, GH deficiency research, tesamorelin IGF-1, elevated IGF-1, high IGF-1, tesamorelin side effects, injection site reaction, joint pain, muscle pain, edema, fluid retention, swelling, carpal tunnel research, glucose intolerance, diabetes, malignancy warning, cancer research, active malignancy, pituitary tumor, hypopituitarism, pituitary surgery, pregnancy, tesamorelin pregnancy, Egrifta pregnancy, FDA approved tesamorelin, FDA approved peptide, FDA approved GHRH, tesamorelin FDA status, Egrifta FDA approval, Egrifta WR approval, compounded tesamorelin, research tesamorelin, gray market tesamorelin, tesamorelin vial, Egrifta vs research tesamorelin, tesamorelin vs sermorelin, sermorelin vs tesamorelin, tesamorelin vs CJC-1295, tesamorelin vs CJC No DAC, tesamorelin vs Modified GRF 1-29, tesamorelin vs ipamorelin, tesamorelin and ipamorelin, tesamorelin vs HGH, tesamorelin vs somatropin, tesamorelin vs semaglutide, tesamorelin vs tirzepatide, tesamorelin vs retatrutide, visceral fat peptide, belly fat peptide, metabolic peptides, growth hormone peptides.

---

Educational Disclaimer: This profile is provided for educational and research-information purposes only. It is not medical advice and does not provide dosing, administration, HIV treatment, hormone therapy, weight-loss protocols, anti-aging therapy, compounding, or purchasing recommendations. Tesamorelin is FDA approved as Egrifta SV and Egrifta WR for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. FDA specifically states that tesamorelin is not indicated for general weight-loss management and is considered weight neutral. Evidence from FDA-approved Egrifta products should not automatically be transferred to research-market or compounded products bearing the tesamorelin name.